Immulogic Pharmaceutical Corporation

Nektar Therapeutics

Merck Patent Gmbh

Aerami Therapeutics, Inc.

Dance Biopharm Inc.

Inhale Therapeutic Systems, Inc.

Savara Inc.

Other

Novartis Ag

The University of North Carolina at Chapel Hill

Aerorx Therapeutics LLC

Heska Corporation

Immulogic Pharamaceutical Corp.

Immulogic Pharmaceutical Co.

Mei-chang Kuo

Bruce L Rogers

John S Patton

Richard D Garman

Yehuda Ivri

Ryan S Patton

Julia L Greenstein

Ze'ev Shaked

Irwin J Griffith

Xian Chen

David Lechuga-Ballesteros

Julian F Bond

Wayne Robert Thomas

Kaw-Yan Chua

Tacey Viegas

Jay Paul Morgenstern

Malcolm Morville

Blaine Bueche

Henry M Franzen

Sean Evans

Chester Leach

Thorunn Rafnar

David G Klapper

Malcolm L Gefter

Pravin L Soni

Linda C Foster

Mark A Exley

John Lord

Stephen P Powers

Herman E Snyder

Jaakko Taneli Jouhikainen

Joanne Pollock

J Milton Harris

Zhihao Fang

Mary J Bossard

Andrew W Brauer

Hema Gursahani

Stewart A Thompson

Thomas J Briner

Yuan Song

Kimberly Perkins

Mohammad Luqman

Shelia R Billingsley

John Nigel Pritchard

Keith Try Ung

John Chan

Matthew Sander

Andrew Clark

Michael A Eldon

C Simone Jude-Fishburn

Scot Cheu

Ze&prime;ev Shaked

C Simone Fishburn

Yiqiong Yuan

William Leung

Sheila R Billingsley

Michael Alex Eldon

Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

Liquid formulations of indacaterol

An aerosolization system includes a container that is configured to deliver a unit dosage of a liquid when squeezed a single time. The system also includes an aerosolizer that is constructed of a housing defining a mouthpiece, and an aerosol generator disposed in the housing. The aerosol generator includes a vibratable membrane having a front face and a rear face, and a vibratable element used to vibrate the membrane. Further, the housing includes an opening that is adapted to receive a unit dosage of the liquid from the container. The opening provides a liquid path to the rear face of the vibratable membrane.

Preservative-free single dose inhaler systems

A method is described for supplying a metered amount of a liquid medicament to an aerosolizing device. The method utilizes a dispenser comprising an elongate dispenser body having a proximal end and a tip at a distal end through which a liquid medicament is dispensed. The dispenser further comprises a dispensing mechanism that operates to dispense a metered quantity of the liquid medicament from the tip each time the dispenser body is compressed. The dispenser is grasped with one hand such that the fingers wrap around the dispenser body, with the thumb closest to the proximal end and the last finger closest to the tip. The tip is inserted into an opening of an inhaler and the elongate body is forced toward the tip to cause the dispenser body to compress, thereby operating the dispensing mechanism and causing a metered quantity of the liquid medicament to eject into the inhaler.

Methods and systems for supplying aerosolization devices with liquid medicaments

Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.

Chemically modified small molecules

Liquid formulations of insulin that contain physically and chemically stable insulin but do not contain preservatives or stabilizers are provided. The formulations also lack surfactants. The formulations are useful for various modes of delivery including pulmonary delivery.

Liquid insulin formulations and methods relating thereto

One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation comprises a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.

Preservative free insulin formulations

Dry powder vancomycin compositions and methods for administering and preparing such compositions are provided.

Dry powder Vancomycin compositions and associated methods

Preservative-free single dose inhaler system

Dry powder vancomycin compositions and associated methods

One embodiment describes an insulin formulation that is specifically adapted for aerosolization. The formulation includes a major amount of water and a minor amount of insulin. Further, the formulation is preservative free, without meta-cresol, cresol or phenol, to permit the formulation to be aerosolized using a vibrating aperture plate without substantial foaming of the insulin formulation.

Growing community of inventors

Palo Alto, CA, United States of America

Mei-chang Kuo